We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLPH
251
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$275K 0.01%
+2,000
New +$311K
OMER icon
252
PUT
Omeros
OMER
$816M
$264K 0.01%
+120
New +$2.74K
ALBO
253
DELISTED
Albireo Pharma Inc
ALBO
$259K 0.01%
7,250
-46,588
-87% -$1.96M
PCYC
254
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$256K 0.01%
10
-19
-66% -$3.67K
LITS
255
CALL
Lite Strategy Inc
LITS
$33M
$252K 0.01%
+70
New +$6.27K
CTSO icon
256
PUT
Cytosorbents Corp
CTSO
$23.3M
$222K 0.01%
+168
New +$1.73K
SCTL
257
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$221K 0.01%
27,196
-828,941
-97% -$3.3M
TNXP icon
258
Tonix Pharmaceuticals
TNXP
$158M
– –
0
– –
APDNW
259
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$190K 0.01%
+186,095
New +$253K
KERX
260
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$188K 0.01%
+14,758
New +$190K
IMNN icon
261
PUT
Imunon
IMNN
$6.43M
– –
-1
Closed -$6.96K
FOMX
262
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$142K 0.01%
15,300
-148,000
-91% -$1.32M
HSTO
263
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
$140K 0.01%
1
– –
TLPH icon
264
PUT
Talphera
TLPH
$67.5M
$120K 0.01%
+16
New +$2.09K
ORKA
265
Oruka Therapeutics
ORKA
$5.46B
$112K ﹤0.01%
+93
New +$109K
CRDF icon
266
Cardiff Oncology
CRDF
$63.6M
$102K ﹤0.01%
208
-70
-25% -$29.9K
ATHX
267
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$99K ﹤0.01%
14
-6
-30% -$362
XNPT
268
CALL
DELISTED
XENOPORT, INC.
XNPT
$98K ﹤0.01%
+137
New +$1.06K
DARA
269
DELISTED
DARA BIOSCIENCES INC COM STK (DE)
DARA
$86K ﹤0.01%
117,370
-7,520
-6% -$6.32K
EXEL icon
270
PUT
Exelixis
EXEL
$14.2B
$57K ﹤0.01%
+220
New +$511
SEEL
271
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
CYTR
272
PUT
DELISTED
CytRx Corp
CYTR
$57K ﹤0.01%
28
+11
+65% +$205
IPCI
273
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$56K ﹤0.01%
1,990
-73
-4% -$1.77K
PSTV icon
274
PUT
Plus Therapeutics
PSTV
$25.9M
– –
0
– –
ALBO
275
PUT
DELISTED
Albireo Pharma Inc
ALBO
$22K ﹤0.01%
6
– –
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.